A cut-off value of 2 cm in tumor size is of prognostic value in surgically treated FIGO stage IB cervical cancer.
OBJECTIVE
Limited knowledge exists about the value of tumor size in surgically treated cervical cancer (CX) using a tumor size of 2 cm as cut-off value.


METHODS
A total of 366 cases of CX FIGO stage IB who received upfront surgery were evaluated regarding tumor size, the prediction of pelvic lymph node involvement, and recurrence-free and overall survival during a median follow-up time of 94 months. Tumors ≤2.0 cm were defined as small, tumors 2.1-4.0 cm as medium sized and those larger than 4 cm as bulky disease.


RESULTS
Small tumors were seen in 28.7%, medium sized in 52.5% and bulky tumors in 18.9%. There was a significant higher frequency of pelvic lymph node involvement with increasing tumor size (13.3% vs. 23.4% vs. 43.5%, respectively; p<0.001) and an increase of recurrent disease (6.7% vs. 18.8% vs. 29.4%, respectively; p<0.001). The 5-year overall survival rate was significantly reduced with increasing tumor size (94.0% vs. 85.1% vs. 69.9%, respectively; p<0.001). Pelvic lymph node involvement and maximal tumor size were independent prognostic factors for both recurrence-free and overall survival in multivariate analysis.


CONCLUSIONS
The results support that tumor size is of prognostic impact in FIGO stage IB cervical carcinomas. A further substaging is suggested for tumors up to 4.0 cm maximum dimension using a cut-off value of 2.0 cm as discriminator. Patients with tumors ≤2.0 cm may represent low risk disease.
Institute of Pathology, Division of Breast, Gynecologic and Perinatal Pathology, University of Leipzig, Germany. Electronic address: hornl@medizin.uni-leipzig.de.
Lars-Christian
LC
Horn
Department of Obstetrics and Gynecology (Institute of Trier), Division of Surgical Gynecologic Oncology, University of Leipzig, Germany.
Karl
K
Bilek
Department of Obstetrics and Gynecology (Institute of Trier), Division of Surgical Gynecologic Oncology, University of Leipzig, Germany.
Uta
U
Fischer
Department of Obstetrics and Gynecology (Institute of Trier), Division of Surgical Gynecologic Oncology, University of Leipzig, Germany.
Jens
J
Einenkel
Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Germany.
Bettina
B
Hentschel
D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000601:surgery*; D055815:Young Adult
Bulky disease; Cervical carcinoma; FIGO; Measurement; Stage IB; Tumor size